About
OptimaCure provides personalized treatment for patients with cancer by repositioning failed cancer drugs. The companys solution employs multiple robust screening approaches that indicate the most appropriate and optimal drug combinations for treating individual cancer patients. The companys process identifies the patients most likely to respond positively to the suggested drug treatment. It can also identify broader applications for the repositioned cancer drugs in treating additional indications. By combining multiple technologies (e.g. in vivo, in vitro, and in silico), OptimaCures proprietary approach enhances the understanding of the mode of action of the selected failed drugs and their combination and repositions them toward the appropriate cancer patients. OptimaCure is a subsidiary of Goldman Hirsh Partners.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is OptimaCure's primary focus in personalized cancer treatment?
- OptimaCure focuses on providing personalized treatment for cancer patients by repositioning failed cancer drugs, using multiple screening approaches to identify optimal drug combinations for individuals.
- When was OptimaCure founded?
- OptimaCure was founded in August 2013.
- What is the operational status of OptimaCure?
- OptimaCure is currently inactive, having ceased operations in January 2019.
- Where is OptimaCure headquartered?
- OptimaCure is headquartered in Herzliya, Israel, at Abba Eban Ave 1.
- How many employees did OptimaCure have?
- OptimaCure had 6 employees.
- What is OptimaCure's relationship with Goldman Hirsh Partners?
- OptimaCure is a subsidiary of Goldman Hirsh Partners.
- What technologies does OptimaCure combine in its approach?
- OptimaCure combines multiple technologies, including in vivo, in vitro, and in silico methods, to understand drug mechanisms and reposition them for cancer patients.
- What is OptimaCure's primary sector classification?
- OptimaCure's primary sector classification is Health Tech & Life Sciences.